About Gauss Surgical
Gauss Surgical is a medical device company. It develops an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery. The company was founded in 2011 and is based in Menlo Park, California. In September 2021, Gauss Surgical was acquired by Stryker.
Research containing Gauss Surgical
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Gauss Surgical in 2 CB Insights research briefs, most recently on Feb 21, 2022.
Expert Collections containing Gauss Surgical
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Gauss Surgical is included in 4 Expert Collections, including AI 100.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Digital Health 150
The most promising digital health startups transforming the healthcare industry
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Gauss Surgical Patents
Gauss Surgical has filed 46 patents.
Latest Gauss Surgical News
Sep 18, 2023
Explore Gauss Surgical: revolutionizing blood loss monitoring with AI technology Gauss Surgical, a medical technology company, is revolutionizing the way blood loss is monitored during surgeries by harnessing the power of artificial intelligence (AI). This innovative approach has the potential to significantly improve patient outcomes and reduce complications associated with excessive blood loss during surgical procedures. Traditionally, blood loss during surgery has been estimated by visually assessing the amount of blood in surgical sponges and suction jars. This method is not only subjective and prone to human error, but it can also lead to inaccurate estimates of blood loss, which can have serious consequences for patients. In some cases, underestimation of blood loss can result in inadequate transfusion, while overestimation can result in unnecessary transfusions, both of which can pose risks to patients. To address this issue, Gauss Surgical has developed an AI-powered platform called Triton, which provides real-time, accurate and objective measurements of blood loss during surgery. The Triton system uses computer vision and machine learning algorithms to analyze images of surgical sponges and suction cartridges, providing accurate measurements of blood loss in real time. This allows surgeons and anesthesiologists to make more informed decisions about patient care, including whether or not to administer blood transfusions. One of the main advantages of the Triton system is its ability to continuously monitor blood loss throughout the duration of a surgical procedure. This is especially important in cases where blood loss may be difficult to predict, such as during complex surgical procedures or in patients with underlying health conditions that may increase the risk of bleeding. By providing real-time feedback on blood loss, the Triton system allows healthcare professionals to quickly identify and resolve any issues that may arise during surgery, improving patient outcomes. In addition to its potential to improve patient care, the Triton system also offers several other benefits for healthcare providers. For example, the AI-powered platform can help reduce costs associated with blood transfusions by ensuring they are only administered when necessary. This is particularly important given the increasing demand for blood products and the associated pressure on healthcare resources. Additionally, the Triton system can also help improve the overall efficiency of surgical procedures by reducing the time spent on manual estimation of blood loss. This can help streamline workflows and allow healthcare professionals to focus on other critical aspects of patient care. The use of AI in healthcare is growing rapidly and Gauss Surgical’s Triton system is a great example of how this technology can be leveraged to improve patient outcomes and revolutionize medical practice. By providing real-time, accurate and objective measurements of blood loss during surgery, the Triton system has the potential to significantly reduce the risks associated with excessive blood loss and improve the overall quality of care for patients. undergoing surgical procedures. As AI continues to advance and become more integrated into healthcare, it is likely that we will see even more innovative applications of this technology in the future. Meanwhile, Gauss Surgical’s Triton system is a shining example of how AI can be used to address critical healthcare challenges and improve patient outcomes. In conclusion, Gauss Surgical’s AI-powered Triton system revolutionizes blood loss monitoring during surgical procedures, providing real-time, accurate and objective measurements that can help improve patient outcomes and reduce complications associated with excessive blood loss. By harnessing the power of AI, this innovative technology has the potential to transform surgical practice and pave the way for even more revolutionary applications of AI in healthcare.
Gauss Surgical Frequently Asked Questions (FAQ)
When was Gauss Surgical founded?
Gauss Surgical was founded in 2011.
Where is Gauss Surgical's headquarters?
Gauss Surgical's headquarters is located at 4085 Campbell Avenue, Menlo Park.
What is Gauss Surgical's latest funding round?
Gauss Surgical's latest funding round is Acquired.
How much did Gauss Surgical raise?
Gauss Surgical raised a total of $54.81M.
Who are the investors of Gauss Surgical?
Investors of Gauss Surgical include Stryker, Northwell Holdings & Ventures, Softbank Ventures Asia, Polaris Partners, OSF HealthCare and 18 more.
Who are Gauss Surgical's competitors?
Competitors of Gauss Surgical include Hemorai.
Compare Gauss Surgical to Competitors
Hemorai develops a portable health solution estimating blood loss levels. It alerts clinicians and physicians of the actual hemoglobin and hematocrit levels and navigates to apply the correct treatment to prevent hemorrhagic shock and unnecessary blood transfusions. The company was formerly known as Onko Solutions. It was founded in 2014 and is based in Austin, Texas.
Abbott (NYSE: ABT) operates as a global healthcare company. It provides a portfolio of science-based offerings in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals. It was founded in 1888 and is based in Abbott Park, Illinois.